The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors
Open accessAbstract
The DNA repair protein PARP-1 emerged as a valuable target in the treatment of tumor entities with deficiencies of BRCA1/2, such as breast cancer. More recently, the application of PARP inhibitors (PARPi) such as olaparib has been expanded to other cancer entities including colorectal cancer (CRC). We previously demonstrated that PARP-1 is overexpressed in human CRC and promotes CRC progression in a mouse model. However, acquired resistance to PARPi and cytotoxicity-mediated adverse effects limit their clinical applicability. Here, we detailed the role of PARP-1 as a therapeutic target in CRC and studied the efficacy of novel PARPi compounds in wildtype (WT) and DNA repair-deficient CRC cell lines together with the chemotherapeutics irinotecan (IT), 5-fluorouracil (5-FU), and oxaliplatin (OXA). Based on the ComPlat molecule archive, we identified novel PARPi candidates by molecular docking experiments in silico, which were then confirmed by in vitro PARP activity measurements. Two promising candidates (X17613 and X17618) also showed potent PARP-1 inhibition in a CRC cell-based assay. In contrast to olaparib, the PARPi candidates caused no PARP-1 trapping and, consistently, were not or only weakly cytotoxic in WT CRC cells and their BRCA2- or ATR-deficient counterparts. Importantly, both PARPi candidates did not affect the viability of nonmalignant human colonic epithelial cells. While both olaparib and veliparib increased the sensitivity of WT CRC cells towards IT, no synergism was observed for X17613 and X17618. Finally, we provided evidence that all PARPi (olaparib > veliparib > X17613 > X17618) synergize with chemotherapeutic drugs (IT > OXA) in a BRCA2-dependent manner in CRC cells, whereas ATR deficiency had only a minor impact. Collectively, our study identified novel lead structures with potent PARP-1 inhibitory activity in CRC cells but low cytotoxicity due to the lack of PARP-1 trapping, which synergized with IT in homologous recombination deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, PARP inhibition was shown to sensitize CRC cells to irinotecan, which was dependent upon homologous recombination deficiency [135].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [135]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057 · cited 1×
“Next, molecular docking with flexible ligands and rigid protein conformation was performed with Glide SP scoring [35].”
MethodFriesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851 · cited 1×
“Finally, the binding poses were visually inspected and re-scored with Glide XP to obtain the binding free energy values [36].”
MethodMadhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9644-8 · Cited by 6,006 · cited 1×
“All protein structures (RCSB PDB: 4PJT [30], 7AAC, 7AAD [31]) were prepared using the Protein Preparation Wizard [32] by adding hydrogen atoms, assigning OPLS3e force field parameters [33], and replacing missing side chains or loops with Prime [34], followed by H-bond assignment optimization and…”
MethodGlobal burden of colorectal cancer: emerging trends, risk factors and prevention strategies
Keum, N., & Giovannucci, E. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0189-8 · Cited by 2,661 · cited 1×
“%) arise through the chromosomal instability pathway (CIN), which is characterized by microsatellite stability (MSS) [6].”
BackgroundDiagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604 · cited 1×
“Current treatment of advanced CRC is based on surgery and chemotherapy with the DNA damage-inducing drugs irinotecan (IT), oxaliplatin (OXA) and 5-fluorouracil (5-FU), which are combined in several chemotherapy regimens [3].”
BackgroundMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456 · cited 2×
“In hereditary CRC, mutations of DNA mismatch repair (MMR) genes such as MLH1 and MSH2 give rise to microsatellite instability (MSI) [5].”
BackgroundRectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rödel, C., Cervantes, A., & Arnold, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx224 · Cited by 2,046
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glimelius, B., Tiret, E., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt240 · Cited by 1,783
On the Role of the Crystal Environment in Determining Protein Side-chain Conformations
Jacobson, M. P., Friesner, R. A., Xiang, Z., & Honig, B. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00470-9 · Cited by 1,267 · cited 1×
“…(RCSB PDB: 4PJT [30], 7AAC, 7AAD [31]) were prepared using the Protein Preparation Wizard [32] by adding hydrogen atoms, assigning OPLS3e force field parameters [33], and replacing missing side chains or loops with Prime [34], followed by H-bond assignment optimization and restraint minimization.”
MethodNew insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226 · cited 1×
“After binding to DNA strand breaks, PARP-1 is activated and catalyzes the post-translational formation of poly ADP-ribose (PAR) on various acceptor proteins, associated with DNA repair, histone modification, or cell cycle progression [13,14].”
Background
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“For instance, PARP inhibition was shown to sensitize CRC cells to irinotecan, which was dependent upon homologous recombination deficiency [135].”
Jiang, C., Yang, S., Wang, Y., Du, L., Niu, M., & Zhang, D. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2542358 · Cited by 7
“PaRylation, a post-translational modification process, is concerned with maintaining genomic stability, DNa repair, and chromatin remodeling 20–22 . studies have shown that PaRP-1 is overexpressed in cRc mouse models and human tissues, driving disease initiation and progression 11,23 .”
Naseri, A., Antikchi, M. H., Soleymani, S., Khosravi, M., Nezameslami, R., Nezameslami, A., Mehdikhani, B., Shirinzadeh-Dastgiri, A., HaghighiKian, S. M., Vakili-Ojarood, M., et al. (2025) · Medeniyet Medical Journal · doi:10.4274/mmj.galenos.2025.72708 · Cited by 2
“PARP-1 might also contribute to the cancer stem cell phenotype, essential for tumor aggressiveness and recurrence 18,21 .”
Bernacchi, A., Valerii, M. C., Spigarelli, R., Dussias, N. K., Rizzello, F., & Spisni, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020649 · Cited by 2
“…particularly relevant in CRC as the resistance to apoptosis is a primary driver of tumor progression and a common mechanism of therapy failure [55,56]. p21 (cyclin-dependent kinase inhibitor 1A or CDKN1A ) acts as the principal inhibitor of cyclin-dependent kinases (CDKs) and regulates cell…”
Aziz, E. H. H., Magdy, A., Zaid, M. A., & Assaf, R. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11159-3 · Cited by 1
Metadata
- Authors
- Demuth, P., Thibol, L., Lemsch, A., Potlitz, F., Schulig, L., Grathwol, C., Manolikakes, G., Schade, D., Roukos, V., Link, A., & Fahrer, J.
- Affiliations
- Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau (DE)
- Universität Greifswald (DE)
- Karlsruhe Institute of Technology (DE)
- Christian-Albrechts-Universität zu Kiel (DE)
- Institute of Molecular Biology (DE)
- Corresponding author
- Fahrer, Jörg
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-10-10
- Volume
- 16
- Issue
- 20
- Pages
- 3441
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11506018
- OpenAlex
- W4403298139
- Cited by
- 14
- References
- 75
- Citations by year
- 2026: 7 · 2025: 7
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository KITopen (Karlsruhe Institute of Technology) (submittedVersion, cc-by)
- KITopen (cc-by)
- Funders
- German Research Foundation (INST 248/331-1 FUGG, INST 292/161-1 FUGG, 2016.039.2)
- Wilhelm Sander Foundation (INST 248/331-1 FUGG, INST 292/161-1 FUGG, 2016.039.2)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- PARP1 inhibition, PARP inhibitors, colorectal cancer, olaparib, veliparib, irinotecan, oxaliplatin, 5-fluorouracil, DNA damage response, BRCA2 deficiency, homologous recombination deficiency, drug synergy, molecular docking, cytotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors. https://app.cochat.ai/papers/10.3390/cancers16203441
- The paper
- Demuth, P., Thibol, L., Lemsch, A., Potlitz, F., Schulig, L., Grathwol, C., Manolikakes, G., Schade, D., Roukos, V., Link, A., & Fahrer, J. (2024). Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors. Cancers. https://doi.org/10.3390/cancers16203441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.